These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 24893880)

  • 1. Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline.
    Aomatsu N; Yashiro M; Kashiwagi S; Kawajiri H; Takashima T; Ohsawa M; Wakasa K; Hirakawa K
    BMC Cancer; 2014 Jun; 14():400. PubMed ID: 24893880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma.
    Kang HJ; Kim IH; Sung CO; Shim JH; Yu E
    Virchows Arch; 2015 Apr; 466(4):403-13. PubMed ID: 25577552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy.
    Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF
    Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
    PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.
    Hussain SA; Ganesan R; Reynolds G; Gross L; Stevens A; Pastorek J; Murray PG; Perunovic B; Anwar MS; Billingham L; James ND; Spooner D; Poole CJ; Rea DW; Palmer DH
    Br J Cancer; 2007 Jan; 96(1):104-9. PubMed ID: 17213826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma.
    Gu M
    Int J Clin Exp Pathol; 2015; 8(1):862-6. PubMed ID: 25755787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
    Generali D; Fox SB; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield SM; Bruzzi P; Bersiga A; Allevi G; Milani M; Aguggini S; Dogliotti L; Bottini A; Harris AL
    Endocr Relat Cancer; 2006 Sep; 13(3):921-30. PubMed ID: 16954440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer.
    Aomatsu N; Yashiro M; Kashiwagi S; Takashima T; Ishikawa T; Ohsawa M; Wakasa K; Hirakawa K
    PLoS One; 2012; 7(9):e45865. PubMed ID: 23049880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Xu L; Che X; Wu Y; Song N; Shi S; Wang S; Li C; Zhang L; Zhang X; Qu X; Teng Y
    Oncol Rep; 2018 May; 39(5):2315-2323. PubMed ID: 29565454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
    Brennan DJ; Jirstrom K; Kronblad A; Millikan RC; Landberg G; Duffy MJ; Rydén L; Gallagher WM; O'Brien SL
    Clin Cancer Res; 2006 Nov; 12(21):6421-31. PubMed ID: 17085655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer.
    Shien T; Kinoshita T; Seki K; Yoshida M; Hojo T; Shimizu C; Taira N; Doihara H; Akashi-Tanaka S; Tsuda H; Fujiwara Y
    Acta Med Okayama; 2013; 67(3):165-70. PubMed ID: 23804139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nine-lncRNA signature predicts distant relapse-free survival of HER2-negative breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy.
    Sun M; Liu X; Xia L; Chen Y; Kuang L; Gu X; Li T
    Biochem Pharmacol; 2021 Jul; 189():114285. PubMed ID: 33069665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival.
    Williams E; Martin S; Moss R; Durrant L; Deen S
    Virchows Arch; 2012 Jul; 461(1):33-9. PubMed ID: 22699808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
    Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
    Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
    Alves WEFM; Bonatelli M; Dufloth R; Kerr LM; Carrara GFA; da Costa RFA; Scapulatempo-Neto C; Tiezzi D; da Costa Vieira RA; Pinheiro C
    BMC Cancer; 2019 Dec; 19(1):1173. PubMed ID: 31795962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer.
    Hong YS; Cho HJ; Kim SY; Jung KH; Park JW; Choi HS; Oh JH; Kim BC; Sohn DK; Kim DY; Chang HJ
    BMC Cancer; 2009 Jul; 9():246. PubMed ID: 19619339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
    Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
    Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
    Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.